Phenomenex Expands Method Development Services
Phenomenex has announced that PhenoLogix, the company’s in-house analytical services group, has moved to an expanded, stand-alone facility. The 9000-squareâfoot laboratory has been designed to develop methods for customers in ultrahighâpressure liquid chromatography (UHPLC), LC, LC coupled to mass spectrometry (MS), and gas chromatography (GC), as well as sample preparation, impurity isolations, chiral screening and smallâ to mediumâscale purifications. PhenoLogix provides support for the company’s product line to customers in drug discovery and development, environmental testing, food safety and quality, forensics, and clinical research. PhenoLogix was cultivated from Phenomenex’s research and development department into a self-contained organization. The new facility features instruments from multiple manufacturers to address a range of applications. Sean Orlowicz, manager of PhenoLogix, commented: “From method development and transfer to understanding the nuances of current sample preparation techniques, our scientists are dedicated to customer support. We provide our services via phone or on-line communication and even at the customer site if necessary.” For more information please visit: www.phenomenex.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
